EU projects coordinated at KI

Denna sida på svenska

Projects within Horizon2020 Health, Demographic Change and Wellbeing

BOOSTB4 – Stem cell therapy before birth against brittle bones disease

  • Project name: Boost Brittle Bones Before Birth 
  • H2020-PHC-2015-single-stage-RTD
  • Project period: 1 January 2016 – 31 December 2020
  • 12 partners
  • Coordinator: Dr Cecilia Götherström

COSYN – Precision medicine in overlapping psychiatric disorders

  • Project name: Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders
  • H2020-PHC-2015-two-stage
  • Project period: 1 January 2016 – 31 December 2020
  • 14 partners
  • Coordinator: Professor Patrick Sullivan

COSYN is a precision medicine programme, with the goal to find an effective therapy for rare individuals with synaptic mutations causal to intellectual disability, autism, and/or schizophrenia. Novel patient-specific neuronal cell models will be developed to investigate the functionality of identified synaptic mutations, with the ultimate goal to be used for screening and identification of approved medications to be evaluated in individualized drug trials.

EDC-MixRisk – Secure chemicals for future generations

  • Project name: Integrating Epidemiology and Experimental Biology to Improve Risk Assessment of Exposure to Mixtures of Endocrine Disruptive Compounds 
  • H2020-PHC-2015-single-stage-RTD
  • Project period: 1 May –  30 April 2019
  • Funding: EUR 6.2 million 
  • 12 partners
  • Coordinator: Associate Professor Åke Bergman, Swetox

SMART2D – Type 2 diabetes prevention and management 

  • SMART2D 2016 logoProject name: Self management approach and reciprocal transfer for type 2 diabetes
  • Horizon 2020 Health – Research and innovation action (RIA)
  • Project period: 2 January 2015 – 31 March 2019 (51 months)
  • 6 partners
  • Coordinator: Professor Stefan Peterson

The aim of SmART2D is to strengthen capacity for T2DM prevention and management through task-shifting among health care providers and community health workers, and expanding care networks through community-based peer support groups, by targeting three populations in different settings.

The objectives are to develop cross-lessons between the low-, middle- and high-income countries; to formulate facility and community strategies to improve access and adherence to prevention and management interventions for T2DM, and implement these strategies through a controlled study design; and to engage in policy dialogue throughout the process.

Collaborative projecs within the Marie Sklodowska-Curie Programme

SyDAD – Training programme focusing on synaptic dysfunktion in Alzheimer's Disease

  • Project name: Synaptic Dysfunction in Alzheimer Disease
  • H2020-MSCA-ETN-2015
  • Project period: 1 november 2015 – 31 okotber 2019
  • Project grant: EUR 3.8 million
  • 6 partners
  • Coordinator: Professor Bengt Winblad

Projects within FP7 theme Health

COUNTERSTROKE – Treatment against stroke

  • Project name: Treating stroke with Affibody molecules targeting the inflammatory mediator HMGB1
  • FP7 Health – Small or medium-scale focused research project
  • Project period: 1 October 2013 – 30 September 2018 (60 months)
  • Project funding: EUR 6 million
  • 6 partners
  • Coordinator: Professor Helena Erlandsson Harris

The COUNTERSTROKE consortium is going to develop molecules targeting the pro-inflammatory protein HMGB1 with the aim to bring a new treatment principle against stroke to clinical reality.

HUMAN – Healthy ageing

  • Project name: Health and understanding of metabolism, aging and nutrition
  • FP7 Health – Large-scale integrating project
  • Project period: 1 October 2013 – 30 August 2018 (60 months)
  • Project funding: EUR 12 million
  • 17 partners
  • Coordinator: Associate Professor Knut R Steffensen

The aim of HUMAN is to gain further insight into the interplay between genetics and physiology of metabolic diseases and longevity. The results gained might provide tools for individuals to better control their own health and ageing through diet and lifestyle.

The project attempts to tackle this fundamental issue by generating 'humanised' mouse models with livers and pancreatic beta cells originating from human donors using stem cell technology, making it possible to study the gene functions in human-derived organs. The human cells to be used originate either from patients affected by severe metabolic diseases or from individuals that enjoyed a complete lack of disease and exceptional longevity; 105 years or more.

INFECT – Improving outcome of necrotizing fasciitis

  • Project name: Systems medicine to understand severe soft tissue infections
  • FP7 Health – Large-scale integrating project
  • Project period: 1 January 2013 – 31 December 2017 (48 months)
  • Project funding: 11,9 million Euro
  • 14 partners
  • Coordinator: Professor Anna Norrby Teglund

Bacteria that normally cause uncomplicated infections can, in rare cases, lead to life-threatening Necrotizing soft tissue infections, NSTIs. Every year, NSTIs kill hundreds of people of all ages in Europe. The disease can also lead to amputation of limbs. Scientists have gathered a wealth of knowledge about NSTIs, but this information is not fully used in clinics yet.

The aim of INFECT is to understand the cause of this disease and to bridge the gap between science and clinical practice. We study the interaction between bacteria and the patients immune defense, how the disease can be diagnosed, and how it should be treated. To do this, we are establishing an international patient registry that ensures a large and informative patient group. INFECT brings together 14 partners from various European and American universities and hospitals.

Projects within Innovative Medicines Initiative (IMI)

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

BTCure – Rheumatoid arthritis

The aim of this initiative is to bring together academic rheumatology research and research in pharmaceutical companies in Europe to further broaden our knowledge of disease causing factors and disease progression in Rheumatoid Arthritis (RA), thereby identifying improved or targeted therapeutic treatments.

The focus of BTCure will be the development of new diagnostic methods to discover the early forms of RA as well as tools to separate the different forms of RA, where different molecular mechanisms are involved and where different therapies may be required.

Projects within the EU Joint Programme - Neurodegenerative Disease Research (JPND)

CeBioND – Impairments in mitochondrial functions may trigger neurodegenerative disorders

  • CeBioND – Cellular bioenergetics in neurodegenerative diseases: a system-based pathway and target analysis
  • Project period: 1 January 2015 – 31 December 2017 (36 months)
  • 5 partners
  • Coordinator: Professor Maria Ankarcrona

Mitochondria are parts of every cell that provide energy to enable cells to perform their day-to-day duties. However mitochondria can also kill cells by producing damaging molecules or by initiating a cell suicide program. These processes are believed to play a key role in the degenerative changes associated with Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.

The CeBioND project aims to understand if impairments in mitochondrial functions are sufficient to trigger these neurodegenerative disorders, or of they represent an additional risk factor for developing the disease.

DAMNPATHS – Molecular pathways leading to selective neuronal cell death

  • Project name: Elucidation of common transcriptional targets in vulnerable dopamine, motorneuron and frontotemporal dementia disease pathways
  • Project period: 1 January 2015 – 31 December 2017 (36 months)
  • 5 partners
  • Coordinator: Associate Professor Eva Hedlund

The goal of the DAMNPATHS project is to identify shared molecular pathways leading to selective neuronal cell death in a group of clinically distinct neurodegenerative diseases: amyotrophic lateral sclerosis (ALS), spinal muscular atrophy and spinobulbar muscular atrophy - all characterized by the loss of neurons that control voluntary muscles.

The aim is to discover key pathways at a stage of disease that may still be reversible, thus opening new avenues for the development of disease-modifying agents that can alleviate the burden of these devastating diseases.

MIND-AD – Prevention strategies for Alzheimer’s disease/dementia

  • Project name: Multimodal preventive trials for Alzheimer’s disease: towards multinational strategies
  • Project period: 1 January 2015 – 31 December 2017 (36 months)
  • 5 partners
  • Coordinator: Professor Miia Kivipelto

The anticipated pandemic increase in the number of Alzheimer disease (AD) and dementia cases carries serious implications for society. The goal of MIND-AD project is to identify effective prevention strategies for Alzheimer’s disease/dementia tailored to different “at-risk” groups.